Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

ZUNVEYL represents a significant advancement in Alzheimer’s care and it is only the second oral AD treatment to be approved in more than a decade. Alpha Cognition’s leadership team will ...

About ZUNVEYL ZUNVEYL was approved in July 2024 by the U.S. FDA. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the ...

ZUNVEYL is a next generation acetylcholinesterase inhibitor approved in the US for the treatment of mild-to-moderate Alzheimer’s disease. Terms of the agreement total $44 million, which includes ...